Asset Acquisition, Contingent Value Right, Number of Milestones

No definition available.

Asset Acquisition, Number of Preclinical Therapies

No definition available.

Collaborative Arrangement, Rights and Obligations, Cumulative Milestone Payment Expense Recognized to Date

No definition available.

Collaborative Arrangement, Rights and Obligations, Make Whole Payment Per Unit

No definition available.

Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments

No definition available.

Collaborative Arrangement, Rights and Obligations, Patent Costs

No definition available.

Collaborative Arrangement, Rights and Obligations, Percent of Payments From Sublicensing

No definition available.

Collaborative Arrangement, Rights And Obligations, Upfront Fee

No definition available.

Contract With Customer, Revenue Recognized to Date From Milestone Payments

No definition available.

Debt Instrument, Number Of Quarterly Payments

No definition available.

Debt Instrument, Remaining Contingent Consideration, Liability

No definition available.

Payment for Asset Acquisition Contingent Consideration Liability Operating Activities

No definition available.

Revenue, Remaining Performance Obligation, Variable Consideration Amount

No definition available.

Royalty Agreement, Buyout Option, Percentage of Net Present Value of Royalty Payments

No definition available.

Royalty Agreement, Payment Received

No definition available.

Royalty Agreement, Period After Public Launch to Terminate Agreement

No definition available.

Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 30
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 30
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498

Amount of liability recognized from contingent consideration in asset acquisition.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 15
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492

Amount of the required periodic payments including both interest and principal payments.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823

Number of units of goods that must be purchased within the specified time period of the agreement to avoid penalties or unfavorable effects on pricing, among other adverse consequences.

No definition available.

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

No definition available.

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227